TELA Bio（NASDAQ:TELA）報告稱，第四季度每股虧損$0.23，低於分析師預期的$0.22，低於預期4.55%。與去年同期每股虧損$0.53相比，這是虧損減少56.6%。公司報告的季度銷售額爲$1764.9萬，低於分析師預期的$2316.6萬，低於預期23.82%。相比去年同期的$1699.8萬，銷售額增長了3.83%。
TELA Bio (NASDAQ:TELA) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.22) by 4.55 percent. This is a 56.6 percent increase over losses of $(0.53) per share from the same period last year. The company reported quarterly sales of $17.649 million which missed the analyst consensus estimate of $23.166 million by 23.82 percent. This is a 3.83 percent increase over sales of $16.998 million the same period last year.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。